207 related articles for article (PubMed ID: 36543771)
41. Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet.
Gibbons E; Minor BMN; Hammes SR
Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 37410387
[TBL] [Abstract][Full Text] [Related]
42. Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells.
Li C; Lee PS; Sun Y; Gu X; Zhang E; Guo Y; Wu CL; Auricchio N; Priolo C; Li J; Csibi A; Parkhitko A; Morrison T; Planaguma A; Kazani S; Israel E; Xu KF; Henske EP; Blenis J; Levy BD; Kwiatkowski D; Yu JJ
J Exp Med; 2014 Jan; 211(1):15-28. PubMed ID: 24395886
[TBL] [Abstract][Full Text] [Related]
43. Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.
Krymskaya VP
Proc Am Thorac Soc; 2008 Jan; 5(1):119-26. PubMed ID: 18094094
[TBL] [Abstract][Full Text] [Related]
44. Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis.
Cai X; Pacheco-Rodriguez G; Fan QY; Haughey M; Samsel L; El-Chemaly S; Wu HP; McCoy JP; Steagall WK; Lin JP; Darling TN; Moss J
Am J Respir Crit Care Med; 2010 Dec; 182(11):1410-8. PubMed ID: 20639436
[TBL] [Abstract][Full Text] [Related]
45. Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: relevance to pulmonary lymphangioleiomyomatosis.
Goncharova EA; Goncharov DA; Damera G; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
Mol Pharmacol; 2009 Oct; 76(4):766-77. PubMed ID: 19596836
[TBL] [Abstract][Full Text] [Related]
46. Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs.
Prizant H; Sen A; Light A; Cho SN; DeMayo FJ; Lydon JP; Hammes SR
Mol Endocrinol; 2013 Sep; 27(9):1403-14. PubMed ID: 23820898
[TBL] [Abstract][Full Text] [Related]
47. Lymphangioleiomyomatosis.
Xu KF; Xu W; Liu S; Yu J; Tian X; Yang Y; Wang ST; Zhang W; Feng R; Zhang T
Semin Respir Crit Care Med; 2020 Apr; 41(2):256-268. PubMed ID: 32279296
[TBL] [Abstract][Full Text] [Related]
48. Neutrophil elastase from myeloid cells promotes TSC2-null tumor growth.
Taya M; Garcia-Hernandez ML; Rangel-Moreno J; Minor B; Gibbons E; Hammes SR
Endocr Relat Cancer; 2020 Apr; 27(4):261-274. PubMed ID: 32045362
[TBL] [Abstract][Full Text] [Related]
49. Connectivity Map Analysis of a Single-Cell RNA-Sequencing -Derived Transcriptional Signature of mTOR Signaling.
Al Mahi N; Zhang EY; Sherman S; Yu JJ; Medvedovic M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922083
[TBL] [Abstract][Full Text] [Related]
50. Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis.
Gibbons E; Taya M; Wu H; Lopa SH; Moss J; Henske EP; McCormack FX; Hammes SR
Endocr Relat Cancer; 2024 Jun; 31(6):. PubMed ID: 38614127
[TBL] [Abstract][Full Text] [Related]
51. Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells.
Sun Y; Gu X; Zhang E; Park MA; Pereira AM; Wang S; Morrison T; Li C; Blenis J; Gerbaudo VH; Henske EP; Yu JJ
Cell Death Dis; 2014 May; 5(5):e1231. PubMed ID: 24832603
[TBL] [Abstract][Full Text] [Related]
52. Lymphangioleiomyomatosis: a metastatic lung disease.
Kundu N; Holz MK
Am J Physiol Cell Physiol; 2023 Feb; 324(2):C320-C326. PubMed ID: 36571446
[TBL] [Abstract][Full Text] [Related]
53. TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.
Liu HJ; Lizotte PH; Du H; Speranza MC; Lam HC; Vaughan S; Alesi N; Wong KK; Freeman GJ; Sharpe AH; Henske EP
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669930
[TBL] [Abstract][Full Text] [Related]
54. Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis.
Cai X; Pacheco-Rodriguez G; Haughey M; Samsel L; Xu S; Wu HP; McCoy JP; Stylianou M; Darling TN; Moss J
Chest; 2014 Jan; 145(1):108-112. PubMed ID: 24051985
[TBL] [Abstract][Full Text] [Related]
55. Doxycycline reduces the migration of tuberous sclerosis complex-2 null cells - effects on RhoA-GTPase and focal adhesion kinase.
Ng HY; Oliver BG; Burgess JK; Krymskaya VP; Black JL; Moir LM
J Cell Mol Med; 2015 Nov; 19(11):2633-46. PubMed ID: 26282580
[TBL] [Abstract][Full Text] [Related]
56. The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis.
Strizheva GD; Carsillo T; Kruger WD; Sullivan EJ; Ryu JH; Henske EP
Am J Respir Crit Care Med; 2001 Jan; 163(1):253-8. PubMed ID: 11208653
[TBL] [Abstract][Full Text] [Related]
57. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis.
Sato T; Seyama K; Fujii H; Maruyama H; Setoguchi Y; Iwakami S; Fukuchi Y; Hino O
J Hum Genet; 2002; 47(1):20-8. PubMed ID: 11829138
[TBL] [Abstract][Full Text] [Related]
58. Effect of beta-agonists on LAM progression and treatment.
Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
[TBL] [Abstract][Full Text] [Related]
59. Novel developments in the study of estrogen in the pathogenesis and therapeutic intervention of lymphangioleiomyomatosis.
Tai J; Liu S; Yan X; Huang L; Pan Y; Huang H; Zhao Z; Xu B; Liu J
Orphanet J Rare Dis; 2024 Jun; 19(1):236. PubMed ID: 38877584
[TBL] [Abstract][Full Text] [Related]
60. [Pulmonary lymphangioleiomyomatosis (LAM)].
Theegarten D; Hager T
Pathologe; 2021 Feb; 42(1):35-39. PubMed ID: 33420570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]